Neurol. praxi. 2025;26(1):61-66 | DOI: 10.36290/neu.2024.042

Study of gut microbiota in the context of neurological disorders

RNDr. Radka Roubalová, Ph.D., RNDr. Petra Procházková, Ph.D.
Laboratoř buněčné a molekulární imunologie
Mikrobiologický ústav AV ČR, v. v. i., Praha-Krč

The gut microbiota has recently come to the forefront of scientific interest, particularly due to its broad spectrum of action not only on tissues that it comes into direct contact with, but also - through a variety of agents - on distant tissues and organs. There are a number of previously described mechanisms through which gut-colonizing microorganisms can affect the host's immune or endocrine systems as well as the central nervous system and behaviour of the host. A number of research teams are studying the microbiome in relation to neurological diseases, investigating the possible effect of specific microorganisms and microbial metabolites on the development and progression of these diseases. This publication deals with those diseases that have been most widely studied and described in this context.

Keywords: microbiome-gut-brain axis, neuropeptides, short-chain fatty acids, autism spectrum disorder, Parkinson's disease, Alzheimer's disease, multiple sclerosis.

Received: June 5, 2024; Revised: June 5, 2024; Accepted: June 6, 2024; Prepublished online: June 6, 2024; Published: March 19, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Roubalová R, Procházková P. Study of gut microbiota in the context of neurological disorders. Neurol. praxi. 2025;26(1):61-66. doi: 10.36290/neu.2024.042.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • PDF will be unlocked 19.3.2026

    References

    1. Agus A, Clement K, Sokol H. Gut microbiota­‑derived metabolites as central regulators in metabolic disorders. Gut. 2021;70(6):1174-1182. Go to original source... Go to PubMed...
    2. Borghammer P, Van Den Berge N. Brain­‑First versus Gut­‑First Parkinson's Disease: A Hypothesis. J Parkinsons, DiS. 2019;9(s2):S281-S295. Go to original source... Go to PubMed...
    3. Brandebura AN, Paumier A, Onur TS, et al. Astrocyte contribution to dysfunction, risk and progression in neurodegenerative disorders. Nat Rev Neurosci. 2023;24(1):23-39. Go to original source... Go to PubMed...
    4. Braniste V, Al­‑Asmakh M, Kowal C, et al. The gut microbiota influences blood­‑brain barrier permeability in mice. Sci Transl Med. 2014;6(263):263ra158. Go to original source... Go to PubMed...
    5. Bronzini M, Maglione A, Rosso R, et al. Feeding the gut microbiome: impact on multiple sclerosis. Front Immunol. 2023;14:1176016. Go to original source... Go to PubMed...
    6. Cattaneo A, Cattane N, Galluzzi S, et al. Association of brain amyloidosis with pro­‑inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiol Aging. 2017;49:60-68. Go to original source... Go to PubMed...
    7. Cryan JF, O'Riordan KJ, Cowan CSM, et al. The Microbiota­‑Gut­‑Brain Axis. Physiol Rev. 2019;99(4):1877-2013. Go to original source... Go to PubMed...
    8. Friedland RP, Chapman MR. The role of microbial amyloid in neurodegeneration. PLoS Pathog. 2017;13(12):e1006654. Go to original source... Go to PubMed...
    9. Hilton D, Stephens M, Kirk L, et al. Accumulation of alpha­‑synuclein in the bowel of patients in the pre­‑clinical phase of Parkinson's disease. Acta Neuropathol. 2014;127(2):235-241. Go to original source... Go to PubMed...
    10. Huang B, Chau SWH, Liu Y, et al. Gut microbiome dysbiosis across early Parkinson's disease, REM sleep behavior disorder and their first­‑degree relatives. Nat Commun. 2023;14(1):2501. Go to original source... Go to PubMed...
    11. Hughes LE, Smith PA, Bonell S, et al. Cross­‑reactivity between related sequences found in Acinetobacter sp., Pseudomonas aeruginosa, myelin basic protein and myelin oligodendrocyte glycoprotein in multiple sclerosis. J Neuroimmunol. 2003;144(1-2):105-115. Go to original source... Go to PubMed...
    12. Hung CC, Chang C, Huang CW, et al. Gut microbiota in patients with Alzheimer's disease spectrum: a systematic review and meta­‑analysis. Aging (Albany NY). 2022;14(1):477-496. Go to original source... Go to PubMed...
    13. Jemimah S, Chabib CMM, Hadjileontiadis L, et al. Gut microbiome dysbiosis in Alzheimer's disease and mild cognitive impairment: A systematic review and meta­‑analysis. PLoS One. 2023;18(5):e0285346. Go to original source... Go to PubMed...
    14. Kang DW, Adams JB, Coleman DM, et al. Long­‑term benefit of Microbiota Transfer Therapy on autism symptoms and gut microbiota. Sci Rep. 2019;9(1):5821. Go to original source... Go to PubMed...
    15. Kinashi Y, Hase K. Partners in Leaky Gut Syndrome: Intestinal Dysbiosis and Autoimmunity. Front Immunol. 2021;12:673708. Go to original source... Go to PubMed...
    16. Lee YK, Menezes JS, Umesaki Y, et al. Proinflammatory T­‑cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2011;108(Suppl 1):4615-4622. Go to original source... Go to PubMed...
    17. Liu B, Fang F, Pedersen NL, et al. Vagotomy and Parkinson disease: A Swedish register­‑based matched­‑cohort study. Neurology. 2017;88(21):1996-2002. Go to original source... Go to PubMed...
    18. Mirza A, Forbes JD, Zhu F, et al. The multiple sclerosis gut microbiota: A systematic review. Mult Scler Relat Disord. 2020;37:101427. Go to original source... Go to PubMed...
    19. Ochoa­‑Reparaz J, Mielcarz DW, Ditrio LE, et al. Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis. J Immunol. 2009;183(10):6041-6050. Go to original source... Go to PubMed...
    20. Peralta­‑Marzal LN, Rojas­‑Velazquez D, Rigters D, et al. A robust microbiome signature for autism spectrum disorder across different studies using machine learning. Sci Rep. 2024;14(1):814. Go to original source... Go to PubMed...
    21. Romano S, Savva GM, Bedarf JR, et al. Meta­‑analysis of the Parkinson's disease gut microbiome suggests alterations linked to intestinal inflammation. NPJ Parkinsons, DiS. 2021;7(1):27. Go to original source... Go to PubMed...
    22. Sampson TR, Debelius JW, Thron T, et al. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease. Cell. 2016;167(6):1469-1480 e1412. Go to original source... Go to PubMed...
    23. Schepici G, Silvestro S, Bramanti P, et al. The Gut Microbiota in Multiple Sclerosis: An Overview of Clinical Trials. Cell Transplant. 2019;28(12):1507-1527. Go to original source... Go to PubMed...
    24. Seo DO, O'Donnell D, Jain N, et al. ApoE isoform- and microbiota­‑dependent progression of neurodegeneration in a mouse model of tauopathy. Science. 2023;379(6628):eadd1236. Go to original source... Go to PubMed...
    25. Shahi SK, Freedman SN, Murra AC, et al. Prevotella histicola, A Human Gut Commensal, Is as Potent as COPAXONE(R) in an Animal Model of Multiple Sclerosis. Front Immunol. 2019;10:462. Go to original source... Go to PubMed...
    26. Sharon G, Cruz NJ, Kang DW, et al. Human Gut Microbiota from Autism Spectrum Disorder Promote Behavioral Symptoms in Mice. Cell. 2019;177(6):1600-1618 e1617. Go to original source... Go to PubMed...
    27. Vuong HE, Pronovost GN, Williams DW, et al. The maternal microbiome modulates fetal neurodevelopment in mice. Nature. 2020;586(7828):281-286. Go to original source... Go to PubMed...
    28. Yip BHK, Leonard H, Stock S, et al. Caesarean section and risk of autism across gestational age: a multi­‑national cohort study of 5 million births. Int J Epidemiol. 2017;46(2):429-439. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.